Article
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
AIDS research and human retroviruses - 1 Nov 2009
Chi Benjamin H, Ellis Giovanina M, Chintu Namwinga, Cantrell Ronald A, Sinkala Moses, Aldrovandi Grace M, Warrier Ranjit, Mbewe Felistas, Nakamura Kyle, Stringer Elizabeth M, Frenkel Lisa M, Stringer Jeffrey S A
Abstract excerpt
A single dose of tenofovir/emtricitabine (TDF/FTC) during labor significantly reduces peripartum nevirapine-associated viral drug resistance when measured by consensus HIV sequencing. It is unknown whether this effect extends to HIV subpopulations of <25-50%. We conducted a randomized trial of single-dose TDF/FTC added to peripartum nevirapine to reduce drug resistance associated with nonnucleoside reverse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.